For decades, weight loss was presented as a simple equation: eat less, exercise more and rely on willpower. That explanation was easy to repeat, but it failed to account for the biology that makes substantial weight reduction difficult to achieve—and even harder to maintain.
The World Health Organization now describes obesity as a chronic, relapsing disease shaped by complex interactions among genetics, neurobiology, eating behaviour, access to nutritious food and the wider environment. In 2022, approximately 890 million adults worldwide were living with obesity.
This change in understanding has transformed medical treatment. Weight-management medicines are no longer viewed merely as temporary appetite suppressants. They are increasingly used as part of structured, long-term care that may also address high blood pressure, abnormal blood glucose, sleep apnoea, cardiovascular risk and other obesity-related complications.
The key question is therefore no longer, “Which product makes weight fall fastest?” A better question is, “Which treatment best matches this person’s health risks, biology, preferences and capacity for long-term follow-up?”
Suggested image: A professional landscape composition showing a clinician’s weight-management desk with a body-composition chart, measuring tape, balanced meal elements and generic oral and injectable treatment formats. Caption: “Modern obesity care combines medical assessment, appropriate treatment, nutrition, movement and long-term monitoring.”
Obesity Treatment Begins Before the Prescription
Body mass index, or BMI, remains a widely used screening measure. It is calculated by dividing weight in kilograms by height in metres squared:
BMI = weight in kilograms ÷ height² in metres
For example, a person who weighs 96 kilograms and is 1.75 metres tall has a BMI of:
96 ÷ (1.75 × 1.75) = 31.3 kg/m²
BMI is useful for identifying population-level risk, but it does not directly measure body-fat distribution, muscle mass or metabolic health. A proper clinical assessment may also include waist circumference, blood pressure, blood glucose, lipid levels, liver health, sleep quality, current medicines and previous weight-management attempts.
Potential contributors such as hypothyroidism, medications associated with weight gain, sleep apnoea, binge-eating disorder and other health conditions may need to be investigated before a treatment plan is chosen.
In many regulatory systems, prescription obesity medication is considered for adults with a BMI of at least 30 kg/m², or at least 27 kg/m² when a weight-related condition such as hypertension, type 2 diabetes or dyslipidaemia is also present. Individual labels, national guidelines and reimbursement rules may differ.
The New Generation: Treatments That Influence Appetite Biology
The greatest recent change in obesity medicine has come from therapies that act on incretin pathways.
Glucagon-like peptide-1, or GLP-1, is a hormone involved in appetite, glucose regulation and communication between the digestive system and brain. GLP-1 receptor agonists can increase feelings of fullness, reduce hunger and slow gastric emptying. Tirzepatide acts on both GLP-1 and glucose-dependent insulinotropic polypeptide, known as GIP, receptors.
The European Association for the Study of Obesity’s 2026 evidence update reviewed 62 randomized clinical trials. It found that the available medicines produced different degrees of total body-weight reduction, with tirzepatide and semaglutide occupying the highest positions for weight-loss efficacy within the periods studied. The framework emphasizes that treatment should be personalized according to complications and therapeutic goals rather than reduced to one universal drug ranking.
Semaglutide
Semaglutide is a GLP-1 receptor agonist, but the product name and approved indication matter.
Wegovy is specifically labelled for chronic weight management in eligible patients. In the United States, injectable Wegovy is also indicated to reduce major cardiovascular events in adults with established cardiovascular disease and overweight or obesity. Ozempic and Rybelsus also contain semaglutide, but their regulatory indications, strengths, dosage schedules and delivery formats are not automatically interchangeable with those of Wegovy.
This is an important purchasing distinction. Sharing an active ingredient does not mean that two branded products have the same indication, dosing instructions or clinical evidence.
Tirzepatide
Tirzepatide activates both GIP and GLP-1 receptors. Zepbound is labelled in the United States for long-term weight reduction in eligible adults and for moderate-to-severe obstructive sleep apnoea in adults with obesity. Mounjaro contains the same active ingredient but was originally approved for type 2 diabetes treatment.
The current Zepbound label begins treatment at 2.5 mg once weekly for four weeks and then uses staged increases. The 2.5 mg strength is an initiation dose rather than an approved maintenance dose. Gradual escalation is intended to improve gastrointestinal tolerability.
Liraglutide
Liraglutide is an earlier GLP-1 receptor agonist. Unlike once-weekly semaglutide and tirzepatide, weight-management liraglutide is generally administered daily. It can remain an appropriate option when its indication, evidence, availability and patient preferences fit the treatment plan.
Greater average efficacy does not make newer medicine automatically suitable for every patient. Cost, availability, gastrointestinal tolerance, cardiovascular history, concurrent medication, pregnancy plans and willingness to use injections may all influence the decision.
Oral Medicines Still Have an Important Role
Not every patient needs or wants an injectable incretin therapy. Older oral treatments work through different mechanisms and may be appropriate for selected individuals.
Orlistat: Reducing Dietary-Fat Absorption
Orlistat acts within the gastrointestinal tract by inhibiting lipases, the enzymes needed to digest part of the fat in food. A portion of dietary fat therefore passes through the digestive system without being absorbed.
Its effects depend strongly on meal composition. High-fat meals increase the likelihood of oily spotting, urgency, loose stools and other gastrointestinal effects. Because orlistat can reduce the absorption of fat-soluble vitamins, the prescribing information recommends attention to vitamin supplementation and appropriate separation of the multivitamin from the medicine.
Orlistat illustrates an important principle: side effects frequently reflect the drug’s mechanism. Understanding that mechanism helps patients adapt their diet and use the treatment more successfully.
Naltrexone and Bupropion: Addressing Appetite and Reward Pathways
The extended-release combination of naltrexone and bupropion acts on neurological pathways associated with appetite and food-related reward.
It is not suitable for everyone. Because the product contains bupropion, its contraindications and warnings include issues related to seizure risk, uncontrolled hypertension, certain eating disorders and concurrent use of other bupropion-containing medicines. Naltrexone blocks opioid receptors, making the combination unsuitable for people using opioid pain medicines or undergoing some forms of opioid treatment.
The safety and effectiveness of combining it with other prescription, over-the-counter or herbal weight-loss products have not been established.
Metformin, Topiramate and Other Medicines
Some medicines found in weight-management catalogues were developed primarily for other conditions.
Metformin is principally a diabetes medicine and is also used in selected patients with insulin resistance or polycystic ovary syndrome. Weight reduction is often modest and variable.
Topiramate is an antiseizure medicine that may reduce appetite, but it has cognitive, neurological and pregnancy-related risks. In some countries, topiramate is approved for weight management only as part of a specific combination with phentermine—not simply as interchangeable topiramate monotherapy.
Other diabetes medicines may produce weight loss as a secondary effect without being approved as obesity treatments. The presence of a product in a weight-loss category should therefore never replace verification of its exact indication.
Not Every Product in a Weight-Loss Category Treats Obesity
A broad online category may include:
- Medicines approved specifically for chronic weight management
- Diabetes medicines that can affect body weight
- Treatments used off-label in selected patients
- Supplements marketed for metabolism or appetite
- Products intended for localized aesthetic contouring
- Injectable solutions that do not produce systemic weight loss
These groups are not equivalent.
Deoxycholic-acid products, for example, are intended to disrupt fat cells in a localized treatment area when used within an appropriate regulatory and clinical framework. They are not substitutes for obesity treatment and do not address visceral fat, appetite regulation or the metabolic consequences of excess body weight.
The OKDERMO weight-loss and obesity-treatment collection currently brings together 52 listings across several of these groups, including semaglutide and tirzepatide formats, liraglutide, orlistat, naltrexone–bupropion, metformin and localized contouring products. Because the collection spans different indications and mechanisms, customers should compare the active ingredient and approved purpose—not merely the category name.
Understanding Percentage Weight Loss
Clinical studies commonly report weight change as a percentage of starting body weight.
For a person beginning at 110 kilograms:
- A 5% reduction equals 5.5 kilograms.
- A 10% reduction equals 11 kilograms.
- A 15% reduction equals 16.5 kilograms.
- A 20% reduction equals 22 kilograms.
These figures are averages or treatment targets, not guarantees. Individual outcomes vary according to dose tolerance, adherence, starting weight, diabetes status, nutrition, physical activity, sleep, genetics and other factors.
Even a moderate reduction can improve some obesity-related risk markers. Greater weight loss may produce additional benefits for selected conditions, but the best result is not always the lowest possible number on the scale. Functional health, metabolic improvement, preservation of lean tissue and sustainability also matter.
Why Dose Escalation Should Not Be Rushed
People may assume that reaching the highest dose as quickly as possible will accelerate weight loss. Incretin therapy is deliberately escalated gradually because nausea, vomiting, diarrhoea, constipation and abdominal discomfort are common adverse effects.
Severe vomiting or diarrhoea can cause dehydration and contribute to acute kidney injury. GLP-1-based medicines also carry warnings relating to gallbladder disease, pancreatitis, severe gastrointestinal reactions and delayed gastric emptying. Patients should tell healthcare teams about these medicines before surgery or deep sedation because delayed gastric emptying can increase the risk of pulmonary aspiration.
Dose escalation is therefore based on tolerability as well as weight response. Remaining longer at a lower dose may sometimes be more appropriate than pushing forward through persistent adverse effects.
The Thyroid Warning Is Specific
Semaglutide and tirzepatide labels carry boxed warnings because the medicines caused thyroid C-cell tumours in rodents. It remains unknown whether they cause medullary thyroid carcinoma in humans.
They are contraindicated in patients with a personal or family history of medullary thyroid carcinoma and in those with multiple endocrine neoplasia syndrome type 2. This warning does not mean that every common thyroid disorder carries the same risk, but thyroid history should be reviewed accurately with the prescriber.
Symptoms such as a neck mass, persistent hoarseness, difficulty swallowing or unexplained breathing difficulty require medical evaluation.
Pregnancy and Contraception Require Planning
Weight-loss medicines are not used during pregnancy for intentional weight reduction. Current semaglutide and tirzepatide labels advise discontinuation when pregnancy is recognized.
Tirzepatide may also reduce the effectiveness of oral hormonal contraceptives because it delays gastric emptying. Its prescribing information advises switching to a non-oral contraceptive method or adding a barrier method for four weeks after starting treatment and for four weeks following each dose increase.
Patients planning pregnancy should discuss the appropriate discontinuation period with their clinician rather than stopping or continuing treatment without guidance.
Preserving Muscle Matters During Weight Loss
A falling scale does not reveal whether the body is losing fat, muscle, water or a combination of all three.
Significant calorie reduction can reduce lean mass as well as fat mass. This makes adequate protein intake, resistance exercise and clinical monitoring increasingly important during effective pharmacological treatment. The appropriate amount of protein and exercise depends on age, kidney function, mobility, starting diet and other health factors.
Warning signs such as unusual weakness, persistent dizziness, inability to meet nutritional needs or repeated vomiting should not be dismissed as evidence that the medicine is “working.”
Successful obesity treatment should improve health and function—not simply suppress food intake to the point of undernutrition.
Why Weight Often Returns When Treatment Stops
Obesity medications do not permanently erase the biological pressures that defend body weight.
In the SURMOUNT-4 randomized withdrawal trial, participants first received tirzepatide for 36 weeks. Those switched to placebo subsequently regained an average of 14% of body weight during the following 52 weeks, while those who continued tirzepatide lost an additional 5.5%.
This does not mean that every patient must remain on the same medicine forever. It does mean that stopping treatment requires a maintenance plan.
Long-term planning may include continued medication, a change in treatment, nutritional support, resistance training, behavioural care, sleep management and closer weight monitoring. Regain is not evidence of moral failure; it is consistent with obesity’s chronic, relapsing biology.
What to Verify Before Ordering
Customers comparing weight-management products should confirm:
- The exact active ingredient. Similar-looking pens can contain semaglutide, liraglutide, tirzepatide or another medicine.
- The approved indication. A diabetes product and an obesity product may share an ingredient without sharing the same approved use or dosage schedule.
- The strength and delivery system. Confirm whether the package contains a single-dose device, multidose pen, cartridge, vial or tablets.
- The manufacturer and market of origin. Packaging can differ between countries. The manufacturer, batch number, expiry date and seal should be identifiable.
- Storage requirements. Injectable peptide medicines frequently require controlled refrigeration before use. Freezing, excessive heat or unknown temperature exposure may damage a product.
- The complete medical history. Gallbladder disease, pancreatitis, kidney problems, severe gastrointestinal disease, diabetes complications, pregnancy plans, thyroid-cancer history and other medicines can affect suitability.
- Prescription and import rules. Legal requirements differ by jurisdiction. Buyers remain responsible for complying with local prescribing, possession and customs regulations.
- A follow-up plan. Treatment should include monitoring of effectiveness, tolerability, nutrition and relevant health markers.
The Best Treatment Is Not Necessarily the Most Powerful
Modern obesity medicine has achieved results that were difficult to imagine a generation ago. Yet the arrival of highly effective treatments has made careful selection more—not less—important.
Tirzepatide or semaglutide may be appropriate when substantial weight loss or treatment of specific obesity-related complications is the priority. Orlistat may suit a person who prefers a non-systemic oral mechanism and can follow a lower-fat eating pattern. Naltrexone–bupropion may be considered when appetite and reward-related eating patterns are clinically relevant and no contraindication is present. Some patients may benefit from another medicine, metabolic surgery or an intensive lifestyle programme.
No product removes the need to understand why it is being used.
The most effective plan is one that matches the patient’s diagnosis, health risks and preferences; protects muscle and nutritional status; manages adverse effects; and remains realistic over the long term.
Weight-loss treatment has moved beyond chasing a smaller number on the scale. At its best, it is structured medical care for a complex chronic disease.
Medical notice: This article provides general educational information and does not constitute a diagnosis, prescription or individualized treatment recommendation. Prescription weight-management medicines require assessment and monitoring by a qualified healthcare professional. Do not start, combine, increase, stop or substitute these products without appropriate medical guidance. Seek urgent care for severe abdominal pain, persistent vomiting, dehydration, allergic symptoms, breathing or swallowing difficulty, or another serious reaction.